{
    "clinical_study": {
        "@rank": "35107", 
        "arm_group": [
            {
                "arm_group_label": "THC", 
                "arm_group_type": "Active Comparator", 
                "description": "Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC,       dissolved in alcohol. Administered intravenously over 10 minutes.\nLow dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol.  This dose is roughly equivalent to smoking approximately \u00bc of a marijuana cigarette, or \"joint\".   Administered intravenously over 10 minutes.\nMedium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol.  This dose is roughly equivalent to smoking approximately \u00bd of a marijuana cigarette, or \"joint\".  Administered intravenously over 10 minutes."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize the dose-related effects of\n      delta-9-tetrahydrocannabinol (\u22069-THC) in healthy individuals on cerebellum-dependent motor\n      functions."
        }, 
        "brief_title": "Cannabinoids and Cerebellar-Motor Functioning", 
        "condition": [
            "Cannabis", 
            "Psychotic Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Marijuana Abuse", 
                "Psychotic Disorders", 
                "Mental Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have used cannabis at least once in their lifetime\n\n          -  No cannabis use in the past month\n\n          -  Men and women aged 21 to 35 years (extremes included) on the day of the first dosing\n\n        Exclusion Criteria:\n\n          -  Hearing deficits\n\n          -  Psychiatric or mental disorders\n\n          -  Hearing Deficits"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853020", 
            "org_study_id": "1211011055"
        }, 
        "intervention": [
            {
                "arm_group_label": "THC", 
                "description": "Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.\nLow Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol.  This dose is roughly equivalent to smoking approximately \u00bc of a marijuana cigarette, or \"joint\".   Administered intravenously over 10 minutes.\nMedium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol.  This dose is roughly equivalent to smoking approximately \u00bd of a marijuana cigarette, or \"joint\".  Administered intravenously over 10 minutes.", 
                "intervention_name": "THC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrocannabinol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cannabinoids", 
            "Eyeblink Conditioning", 
            "EBC"
        ], 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06516"
                }, 
                "name": "VA Connecticut Healthcare System"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Cannabinoids and Cerebellar-Motor Functioning", 
        "overall_contact": {
            "email": "christina.luddy@yale.edu", 
            "last_name": "Christina Luddy, B.S.", 
            "phone": "203-932-5711", 
            "phone_ext": "4549"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Cerebellum Dependent Associative Learning (% Conditioned Responses)", 
                "safety_issue": "Yes", 
                "time_frame": "+15 minutes after infusion"
            }, 
            {
                "measure": "Grooved Pegboard Motor Task (Reaction Time/Accuracy)", 
                "safety_issue": "Yes", 
                "time_frame": "+55 minutes after infusion"
            }, 
            {
                "measure": "CANTAB Motor Screening Test (Reaction Time/Accuracy)", 
                "safety_issue": "Yes", 
                "time_frame": "+55 minutes after infusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853020"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Patrick D. Skosnik", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinician Administered Dissociative Symptoms Scale (Total Score)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline; +45, +100, +240 minutes after infusion"
            }, 
            {
                "description": "0 being none; 100 being completely", 
                "measure": "Visual Analog Scale, a measure of THC intoxication (Total Score)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline; +45, +100, +240 minutes after infusion"
            }, 
            {
                "measure": "Psychotomimetic States Inventory (Total Score)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline; +45, +100, +240 minutes after infusion"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}